{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:51:13Z","timestamp":1789991473302,"version":"4.0.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2013,4,29]],"date-time":"2013-04-29T00:00:00Z","timestamp":1367193600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0061885","type":"journal-article","created":{"date-parts":[[2013,4,29]],"date-time":"2013-04-29T17:09:36Z","timestamp":1367255376000},"page":"e61885","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":89,"title":["A Single-Dose PLGA Encapsulated Protective Antigen Domain 4 Nanoformulation Protects Mice against Bacillus anthracis Spore Challenge"],"prefix":"10.1371","volume":"8","author":[{"given":"Manish","family":"Manish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Rahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,4,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10254-004-0028-2","article-title":"Anthrax toxins","volume":"152","author":"M Mourez","year":"2004","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","author":"AM Friedlander","year":"1993","journal-title":"J Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.286.20.2554","article-title":"Death due to bioterrorism-related inhalational anthrax: report of 2 patients","volume":"286","author":"L Borio","year":"2001","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1172\/JCI0216204","article-title":"Development of an improved vaccine for anthrax","volume":"110","author":"SH Leppla","year":"2002","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/IAI.00070-07","article-title":"Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge","volume":"75","author":"AU Bielinska","year":"2007","journal-title":"Infect Immun"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2174\/187220811797579097","article-title":"Recent progress in the development of anthrax vaccines","volume":"5","author":"M Kaur","year":"2011","journal-title":"Recent Pat Biotechnol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.mam.2009.07.002","article-title":"Preparedness for an anthrax attack","volume":"30","author":"DR Franz","year":"2009","journal-title":"Mol Aspects Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14787210.7.2.219","article-title":"Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis","volume":"7","author":"J-N Tournier","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"D28","DOI":"10.1016\/j.vaccine.2009.08.102","article-title":"Advances in the development of next-generation anthrax vaccines","volume":"27","author":"AM Friedlander","year":"2009","journal-title":"Vaccine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.addr.2005.01.028","article-title":"Molecular basis for improved anthrax vaccines","volume":"57","author":"RN Brey","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4161\/hv.9777","article-title":"Is new always better than old?: The development of human vaccines for anthrax","volume":"5","author":"LW Baillie","year":"2009","journal-title":"Hum Vaccin"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"39897","DOI":"10.1074\/jbc.M508569200","article-title":"Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen","volume":"280","author":"G Zomber","year":"2005","journal-title":"J Biol Chem"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jps.20484","article-title":"Anthrax Vaccine Powder Formulations for Nasal Mucosal Delivery","volume":"95","author":"GE Jiang","year":"2006","journal-title":"J Pharm Sci"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1002\/jps.23294","article-title":"Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue","volume":"101","author":"L Hu","year":"2012","journal-title":"J Pharm Sci"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0264-410X(97)00268-5","article-title":"Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers","volume":"16","author":"BW McBride","year":"1998","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1128\/CVI.00174-12","article-title":"Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant","volume":"19","author":"L Wagner","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"ref17","first-page":"31","article-title":"Biodegradable Nanoparticles as Vaccine Adjuvants and Delivery Systems: Regulation of Immune Responses by Nanoparticle-Based Vaccine","volume":"247","author":"T Akagi","year":"2012"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.addr.2012.09.004","article-title":"Biodegradation and biocompatibility of PLA and PLGA microspheres","volume":"64","author":"JM Anderson","year":"2012","journal-title":"Advanced Drug Delivery Reviews"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","article-title":"Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier","volume":"3","author":"HK Makadia","year":"2011","journal-title":"Polymers"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4110\/in.2011.11.3.163","article-title":"Formulation and Characterization of Antigen-loaded PLGA Nanoparticles for Efficient Cross-priming of the Antigen","volume":"11","author":"Y-R Lee","year":"2011","journal-title":"Immune Netw"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/IAI.70.4.2022-2028.2002","article-title":"Mucosal or Parenteral Administration of Microsphere-Associated Bacillus anthracis Protective Antigen Protects against Anthrax Infection in Mice","volume":"70","author":"HC Flick-smith","year":"2002","journal-title":"Infect Immun"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/pro.238","article-title":"Domain 4 of the anthrax protective antigen maintains structure and binding to the host receptor CMG2 at low pH","volume":"18","author":"AS Williams","year":"2009","journal-title":"Protein Sci"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/IAI.70.3.1653-1656.2002","article-title":"A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection","volume":"70","author":"HC Flick-Smith","year":"2002","journal-title":"Infect Immun"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1016\/j.vaccine.2011.03.082","article-title":"A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax","volume":"29","author":"J Gorantala","year":"2011","journal-title":"Vaccine"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.bbrc.2005.09.196","article-title":"Advances in alfalfa mosaic virus-mediated expression of anthrax antigen in planta","volume":"338","author":"R Brodzik","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.virol.2006.05.010","article-title":"Rabies virus glycoprotein as a carrier for anthrax protective antigen","volume":"353","author":"ME Smith","year":"2006","journal-title":"Virology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"8300","DOI":"10.1128\/JVI.00183-10","article-title":"Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways","volume":"84","author":"WA Langley","year":"2010","journal-title":"J Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejpb.2012.05.019","article-title":"Biophysical characterisation of thermal-induced precipitates of recombinant anthrax protective antigen: Evidence for kinetically trapped unfolding domains in solid-state","volume":"82","author":"A Ganesan","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"ref29","first-page":"35","article-title":"A statistically defined endpoint titer determination method for immunoassays: J Immunol Methods","volume":"221","author":"A Frey","year":"1998"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2010.12.017","article-title":"Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design","volume":"78","author":"X Li","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1586\/erv.10.89","article-title":"Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses","volume":"9","author":"MO Oyewumi","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.micpath.2004.10.007","article-title":"Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain","volume":"38","author":"HC Flick-Smith","year":"2005","journal-title":"Microb Pathog"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/CVI.00324-12","article-title":"A Three-Dose Intramuscular Injection Schedule of Anthrax Vaccine Adsorbed Generates Sustained Humoral and Cellular Immune Responses to Protective Antigen and Provides Long-Term Protection against Inhalation Anthrax in Rhesus Macaques","volume":"19","author":"CP Quinn","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.molimm.2008.12.031","article-title":"Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis","volume":"46","author":"M Kaur","year":"2009","journal-title":"Mol Immunol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/IAI.51.3.795-800.1986","article-title":"Differences in susceptibility of inbred mice to Bacillus anthracis","volume":"51","author":"SL Welkos","year":"1986","journal-title":"Infect Immun"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e1002512","DOI":"10.1371\/journal.ppat.1002512","article-title":"Mechanisms of pathogenesis, infective dose and virulence in human parasites","volume":"8","author":"HC Leggett","year":"2012","journal-title":"PLoS Pathog"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1128\/IAI.00515-12","article-title":"Dissemination bottleneck in a murine model of inhalational anthrax","volume":"80","author":"RD Plaut","year":"2012","journal-title":"Infect Immun"},{"key":"ref38","first-page":"4118","article-title":"Comparison of the Structural Stability and Dynamic Properties of Recombinant Anthrax Protective Antigen and Its 2-Fluorohistidine-Labeled Analogue","volume":"Sci101","author":"L Hu","year":"2012","journal-title":"J Pharm"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2006.11.063","article-title":"PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice","volume":"331","author":"S Ribeiro","year":"2007","journal-title":"Int J Pharm"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0168-1656(96)01569-6","article-title":"Thermostabilization of protective antigen\u2013the binding component of anthrax lethal toxin","volume":"50","author":"C Radha","year":"1996","journal-title":"J Biotechnol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0006-291X(02)02049-1","article-title":"Gln277 and Phe554 residues are involved in thermal inactivation of protective antigen of Bacillus anthracis","volume":"296","author":"S Singh","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"A Kumari","year":"2010","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1016\/j.biomaterials.2012.03.041","article-title":"Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype","volume":"33","author":"SL Demento","year":"2012","journal-title":"Biomaterials"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"e31472","DOI":"10.1371\/journal.pone.0031472","article-title":"Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine","volume":"7","author":"JJ Moon","year":"2012","journal-title":"PLoS One"},{"key":"ref45","first-page":"2115","article-title":"Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11","volume":"7","author":"DM Santos","year":"2012","journal-title":"Int J Nanomedicine"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1211\/jpp.58.6.0004","article-title":"Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses","volume":"58","author":"MEC Lutsiak","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"F Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1084\/jem.20100995","article-title":"A requirement for Fc\u03b3R in antibody-mediated bacterial toxin neutralization","volume":"207","author":"N Abboud","year":"2010","journal-title":"J Exp Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1073\/pnas.1013083107","article-title":"Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities","volume":"107","author":"TJ Merkel","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.micpath.2005.02.001","article-title":"The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions","volume":"38","author":"CK Cote","year":"2005","journal-title":"Microb Pathog"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0061885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T19:12:54Z","timestamp":1595704374000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0061885"}},"subtitle":[],"editor":[{"given":"Gourapura J.","family":"Renukaradhya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,4,29]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0061885","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,29]]}}}